Predict your next investment

Venture Capital
kytotech.com

See what CB Insights has to offer

Investments

11

About Kyto Technology & Life Science

Kyto Technology & Life Science's strategy is to develop a specialized vehicle for early stage technology and life science companies. Kyto acts as a mentor, advisor, external manager, and investor for privately held companies in the USA, Canada, and Israel.

Kyto Technology & Life Science Headquarter Location

13050 La Paloma Rd

Los Altos, California, 94022,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Kyto Technology & Life Science News

Kyto Technology & Life Science Inc. Announces the Termination of Tender Offer

May 7, 2022

05/07/2022 | 11:55am EDT Message : *Required fields Los Altos Hills, California, May 07, 2022 (GLOBE NEWSWIRE) -- Kyto Technology & Life Science, Inc. (OTCQB: KBPH) (the “Company” or “Kyto”), today announced that it has terminated its previously announced tender offer to allow amendment of outstanding warrants to purchase 1,596,667 shares of common stock in Kyto (the “Original Warrants”) to purchase up to 4,790,001 shares common stock in Kyto (the “Shares”), which was due to expire at 11:59 p.m., San Francisco Time, on May 16, 2022 (the “Tender Offer”), as a result of reassessment of offering conditions. As a result of this termination, no Original Warrants will be amended, and no Shares will be issued, and all Election Forms previously tendered and not withdrawn will be cancelled. The Company may seek opportunities in the future to repurchase Shares from time to time, subject to applicable law. Such future repurchases, if any, may be effectuated through open market purchases under a plan that complies with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), through private purchases or through other similar transactions, and would be subject to market conditions, applicable legal requirements, contractual obligations and other factors. Rule 13e-4(f) under the Exchange Act generally prohibits the Company and its affiliates from purchasing any Shares until at least ten business days after the date the Tender Offer was terminated, subject to certain limited exceptions. *Cautionary Note Regarding Forward-Looking Statements * Kyto has made statements in this press release that are forward-looking statements, including the expected timing, size or other terms of the tender offer and the company’s ability to complete the tender offer. In some cases, you can identify these statements by forward-looking words such as “may”, “will”, “expect”, “plan”, or “believe”, the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about the company may include projections of the company’s future financial performance, based on its growth strategies and anticipated trends in its business. These statements are only predictions based on the company’s current expectations and projections about future events. Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, there are important factors that could cause the company’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks outlined under “Risk Factors” in Kyto’s 2021 Annual Report on Form 10-K and should carefully review the other reports filed by the company with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Kyto is under no duty to, and it does not undertake any obligation to, update or review any of these forward-looking statements after the date of this press release except as required by law. Simon Westbrook

Kyto Technology & Life Science Investments

11 Investments

Kyto Technology & Life Science has made 11 investments. Their latest investment was in Rhaeos as part of their Seed VC on December 12, 2021.

CBI Logo

Kyto Technology & Life Science Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/24/2021

Seed VC

Rhaeos

$2.2M

Yes

6

7/9/2021

Seed VC

Single Pass

Yes

1

6/28/2021

Seed VC

AOA Dx

$2.5M

Yes

3

12/10/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

Subscribe to see more

0

Date

12/24/2021

7/9/2021

6/28/2021

12/10/2020

Round

Seed VC

Seed VC

Seed VC

Series A

Other Investors

Company

Rhaeos

Single Pass

AOA Dx

Subscribe to see more

Subscribe to see more

Amount

$2.2M

$2.5M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

3

10

0

Kyto Technology & Life Science Team

1 Team Member

Kyto Technology & Life Science has 1 team member, including current Chief Executive Officer, Paul M Russo.

Name

Work History

Title

Status

Paul M Russo

Chief Executive Officer

Current

Name

Paul M Russo

Work History

Title

Chief Executive Officer

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.